- Home
- PAVM vs BTAI Comparison
PAVM vs BTAI Comparison
Compare PAVM & BTAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PAVM | BTAI |
|---|---|---|
| Founded | 2014 | 2017 |
| Country | United States | United States |
| Employees | 41 | 29 |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 41.8M | 35.8M |
| IPO Year | N/A | 2018 |
Fundamental Metrics
Financial Performance| Metric | PAVM | BTAI |
|---|---|---|
| Price | $5.45 | $1.11 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $65.00 | $23.00 |
| AVG Volume (30 Days) | 9.6K | ★ 590.7K |
| Earning Date | 05-15-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 75.63 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $603.94 | $197.82 |
| Revenue Next Year | $33.16 | $910.15 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.21 | $1.01 |
| 52 Week High | $28.44 | $8.08 |
Technical Indicators
Market Signals| Indicator | PAVM | BTAI |
|---|---|---|
| Relative Strength Index (RSI) | 27.61 | 43.30 |
| Support Level | $0.34 | $1.05 |
| Resistance Level | $6.63 | $1.39 |
| Average True Range (ATR) | 0.33 | 0.09 |
| MACD | 0.01 | -0.00 |
| Stochastic Oscillator | 4.24 | 10.14 |
Price Performance
Historical ComparisonAbout PAVM PAVmed Inc.
PAVmed Inc is a multi-product, commercial-stage medical technology company organized to advance a broad pipeline of medical technologies from concept to commercialization. The company operates in a single segment as a medical technology company, with the following lines of business: Diagnostics, Medical Devices, and Digital Health. Its products are EsoGuard, EsoCheck, and the Veris Cancer Care Platform.
About BTAI BioXcel Therapeutics Inc.
BioXcel Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on drug development utilizing novel artificial intelligence (AI) to identify the next wave of medicines across neuroscience and immuno-oncology. The pipeline products of the company are BXCL501 and BXCL701. The company's commercial product, IGALMI (developed as BXCL501) is a proprietary, sublingual film formulation of dexmedetomidine approved by the FDA for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.